Agios Pharmaceuticals, Inc.

Cubist Pharmaceuticals, Incorporated

Jacob P Sizemore

Mahmoud Mirmehrabi

You Seok Hwang

Sudhakar Devidasrao Garad

Liting Guo

Jian-Qiao Gu

Yeqing Su

Akash Jain

Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency. 

Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

This disclosure provides compositions containing solid forms of sodium (2S,5R)-2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulfate, and methods of manufacturing and using these compositions.

Crystalline form of a &#x3b2;-lactamase inhibitor

Growing community of inventors

Shrewsbury, MA, United States of America

Jacob P Sizemore